Helix BioPharma (TSE:HBP) Shares Cross Below Fifty Day Moving Average - Here's What Happened

Key Points

• Shares dipped below its 50-day moving average — the 50-day MA is C$1.87, the stock traded as low as C$1.82 and last traded at C$1.88 on a volume of 505 shares.
• Weak financials and elevated leverage — market cap C$143.6M, 200-day MA C$2.16, negative P/E of -31.33, debt-to-equity 2.34, current ratio 0.04 and quick ratio 1.04.
• Clinical-stage oncology pipeline — Helix is advancing L-DOS47 (an antibody-enzyme conjugate) after Phase Ib testing in NSCLC and is developing next-generation CEACAM6-targeting bi-specific ADCs.

Shares of Helix BioPharma Corp. (TSE:HBP - ) passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$1.87 and traded as low as C$1.82. Helix BioPharma shares last traded at C$1.88, with a volume of 505 shares trading hands.

Helix BioPharma Stock Performance

The stock has a 50 day moving average price of C$1.87 and a two-hundred day moving average price of C$2.16. The company has a current ratio of 0.04, a quick ratio of 1.04 and a debt-to-equity ratio of 2.34. The company has a market cap of C$143.59 million, a price-to-earnings ratio of -31.33 and a beta of 0.38.

Helix BioPharma Company Profile

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The Company's pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today's front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix's next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.